The KCCQ summary score, or the disease-specific quality of life, increased similarly between groups. The increase, however, tended to be nine points greater in the DASH/SRD participants—indicating the study did not meet its primary outcome.
The researchers found diet-related adverse events were uncommon. Interestingly, only 11 percent of DASH/SRD participants had HF-related hospital readmissions, compared to 27 percent in the control group. And within the first 30 days of discharge from the hospital, the DASH/SRD group spent 17 cumulative days re-hospitalized, compared to 55 days in the control group.
Overall, the researchers found, sodium restriction did not have a significant impact on blood pressure, serum creatinine or serum potassium in either group.
“The GOURMET-HF results are hypothesis-generating and establish the rationale for conducting a larger study of direct dietary support in patients with HF after hospital discharge,” the researchers concluded. “Such a trial would ideally be powered to assess this strategy’s impact on hospital readmission burden. In addition, the complexity and costs of this intervention, as well as its feasibility and efficacy across patients of diverse demographics and socioeconomic status, would be important considerations in a future trial.”